Menu
Back to Journals » Drug Design, Development and Therapy » Volume 9
Novel synthesizing method of pH-dependent doxorubicin-loaded anti-CD22-labelled drug delivery nanosystem
Authors Sun M, Wang J, Lu Q, Xia G, Zhang Y, Song L, Fang Y
Received 17 April 2015
Accepted for publication 29 May 2015
Published 7 September 2015 Volume 2015:9 Pages 5123—5133
DOI https://doi.org/10.2147/DDDT.S86764
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Prof. Dr. Wei Duan
Mengjiao Sun,1,* Jun Wang,1,* Qin Lu,1 Guohua Xia,2 Yu Zhang,3 Lina Song,3 Yongjun Fang1
1Department of Hematology/Oncology, Nanjing Children’s Hospital, Nanjing Medical University, 2Department of Hematology, Zhongda Hospital, Medical School, Southeast University, 3State Key Laboratory of Bioelectronics, Southeast University, Nanjing, People’s Republic of China
*These authors have contributed equally to this work
Abstract: The objective of this study was to investigate the anticancer efficacy of dimercaptosuccinic acid-modified iron oxide magnetic nanoparticles coloaded with anti-CD22 antibodies and doxorubicin (anti-CD22-MNPs-DOX) on non-Hodgkin’s lymphoma cells. The physical properties of anti-CD22-MNPs-DOX were studied and its antitumor effect on Raji cells in vitro was evaluated using the Cell Counting Kit-8 assay. Furthermore, cell apoptosis and intracellular accumulation of doxorubicin were determined by flow cytometry. The results revealed that anti-CD22-MNPs-DOX inhibited the proliferation of Raji cells, significantly increased the uptake of doxorubicin, and induced apoptosis. Therefore, it was concluded that a coloaded antibody and chemotherapeutic drug with magnetic nanoparticles might be an efficient targeted treatment strategy for non-Hodgkin’s lymphoma.
Keywords: doxorubicin, anti-CD22 antibody, drug delivery system, target selection, non-Hodgkin lymphoma
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.